Ardsley Advisory Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Ardsley Advisory Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,000	Closed	-$265K	–	166
2017 Q2	$265K	Sell	11,000 -5,000	-31%	-$111K	0.04%	120
2017 Q1	$308K	Buy	16,000 +3,500	+28%	+$55.1K	0.05%	118
2016 Q4	$193K	Buy	12,500 +2,500	+25%	+$32.5K	0.03%	118
2016 Q3	$130K	Hold	10,000	–	–	0.02%	147
2016 Q2	$139K	Buy	+10,000	New	+$147K	0.02%	140
2016 Q1	–	Sell	-15,000	Closed	-$285K	–	191
2015 Q4	$285K	Buy	+15,000	New	+$286K	0.04%	110

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ardsley Advisory Partners's PRTK Position: Q3 2017 in Review

Ardsley Advisory Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 11,000 shares — an estimated $265K sold.

Ardsley Advisory Partners first reported a position in PRTK in Q4 2015 and held it in 6 quarters. The position peaked at $308K in Q1 2017. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

Ardsley Advisory Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Ardsley Advisory Partners sold 11,000 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $265K.
Ardsley Advisory Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
Ardsley Advisory Partners's Paratek Pharmaceuticals, Inc. position peaked at $308K in Q1 2017.
133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Ardsley Advisory Partners's 13F filing for Q3 2017, filed 14 Nov 2017.